Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients

NCT06938152 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Osteoporosis
Osteoporosis Postmenopausal

Interventions

DRUG: Romosozumab followed by Denosumab
DRUG: Romosozumab and Denosumab Cycle Therapy

Sponsor

National Taiwan University Hospital